

Completion of \$8 million Oversubscribed Capital Raising

Highlights

- MedAdvisor has successfully raised \$8 million via an institutional placement (Placement)
- Placement was significantly oversubscribed, with strong support from both existing and new shareholders
- Strong participation from leading Australian institutions and pharmacies, providing further industry validation and recognition
- Funding will be used to complete the acquisition of Healthnotes, strengthening MedAdvisor's market position and to fuel additional growth initiatives and scale

MedAdvisor Limited (ASX: **MDR**, the **Company**), Australia's leading digital medication management company, is pleased to announce offers have been accepted to raise \$8 million via an institutional placement (Placement).

200 million new fully paid ordinary shares, raising a total of \$8 million, will be issued at \$0.04 per share representing no discount to the 5 day VWAP and a discount of 10% to the last traded price.

In conjunction with the Placement, 57,894,737 shares will be issued to Healthnotes as part of the acquisition, for a total consideration of \$5.5 million, paid as 60% cash and 40% scrip. The shares are expected to be quoted on the Australia Securities Exchange on the 26th October 2016 and will bring the total shares on issue to 944,881,424.

The Placement was significantly over subscribed and required a scale back. Strong interest was received from existing and new investors, with a number of new and leading Australian institutions joining the shareholder register. Key pharmacy groups also participated in the Placement, providing industry recognition and positive validation of MedAdvisor's offering. The Placement was led by joint managers Peloton Capital and Veritas Securities.

The funds raised will be used for the cash component of the consideration and transaction costs of \$4 million for the acquisition of Healthnotes and \$4m to fuel further growth initiatives, both domestically and internationally.

The acquisition of Healthnotes brings together the two leaders in medication adherence management, strengthening MedAdvisor's strategic position, increasing its market share and accelerating its path to profitability. Key benefits of the acquisition include:

- Increases MedAdvisor's share of connected community pharmacies to 45%, from over 1,600 to over 2,400 Australian community pharmacies
- Increases Australian patients connected to MedAdvisor's platforms from 230,000 to over 500,000 people;
- Increases the number of General Practitioners (GPs) connected to MedAdvisor's platforms to nearly 4,000 GPs;

Robert Read, CEO, MedAdvisor commented on the Placement: "We've received great support and belief in our product and growth strategy from investors. With the acquisition of Healthnotes we will be providing enhanced health outcomes to over half a million Australians and have 45% of Australia's pharmacies subscribed. Furthermore, we can accelerate our growth initiatives as we look to diversify our offering in our domestic market of Australia and seek expansion opportunities in overseas jurisdictions."

For personal use only

For more information

Robert Read, CEO
MedAdvisor
Tel: +61 3 9095 3036
robertr@medadvisor.com.au

Andrew Ramadge
Media and Capital Partners
Tel: +61 475 797 471
andrew.ramadge@mcpartners.com.au

Geoff Barnes, Managing Director
Peloton Capital
Tel: +61 2 8651 7801
Geoff.barnes@pelotoncapital.com.au

About MedAdvisor

MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. Founded with a desire to simplify medication management, the highly automated and intuitive Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records. Available free on mobile and internet devices, the platform also incorporates a variety of valuable and convenient features including reminders and pre-ordering of medications, which together improves adherence by approximately 20%.

Since launching in 2013, MedAdvisor has welcomed over 230,000 registered users through its connections with over 30% of pharmacies across Australia. Upon completion of the recently announced Healthnotes acquisition, these numbers will increase to over 500,000 connected patients and 45% market share of pharmacies across Australia.

For personal use only